Dengue Fever Clinical Trial
Official title:
Factors Associated With Poor Dengue Outcomes in Malaysia
This study aims to analyse the results of national data collected by the e-Dengue Information System in order to determine the factors associated with disease outcomes in all patients registered from January 2013 to December 2014.
Dengue is the most important arthropod borne viral disease in humans. The World Health
Organization has estimated that more than 70% of the global at risk population live in the
WHO southeast Asia and Western Pacific region, which account for nearly 75% of global
disease burden from dengue. The number of reported cases of dengue in Malaysia has increased
fourfold from 44.3 per 100 000 population in 1999 to 181 per 100 000 in 2007. Serologically
confirmed cases are approximately half of the number of reported cases. An increase in
dengue deaths in the adult populations has been observed since 2002. A study in Vietnam
showed that women and children appear to have increased risk of dengue shock syndrome and
death. Children aged 6-10 years had highest risk of Dengue Shock Syndrome (DSS). However,
mortality was highest in younger children. However, in a study of 560 adult dengue patients
in Martinique, Thomas L et al found that severe dengue were mainly in males, elderly, and
presented with abdominal pain, cough and diarrhoea. At present, there is no vaccine or cure
for dengue. Treatment is mainly supportive and for symptom relief. Various measures have
been employed to decrease the incidence of dengue - these have been mainly by public health
measures. However, 2014 has seen a dramatic rise in the number of confirmed dengue cases as
well as mortality.
This study aims to analyse the results of national data collected by the e-Dengue
Information System in order to determine the factors associated with disease outcomes in all
patients registered from January 2013 to December 2014.
An epidemiological observational study will be done by utilizing e-dengue data from year
2013 till year 2014. The inclusion criteria is all dengue cases registered in the e-Dengue
information system 2013-2014; and there is no exclusion criteria.
The primary outcome measurement is the disease outcome which included recovery,
hospitalisation and death.
All data collected will be analyzed by using descriptive analysis, the prevalence/incidence
will be estimated; and regression model will be generated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04514107 -
A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
|
N/A | |
Completed |
NCT00788151 -
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
|
Phase 2 | |
Completed |
NCT02510638 -
The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia
|
N/A | |
Completed |
NCT01666652 -
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
|
Phase 1 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Completed |
NCT01443247 -
Role of Andi-d in Dengue Fever: a Pilot Study
|
N/A | |
Completed |
NCT00831012 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults
|
Phase 1 | |
Completed |
NCT00089908 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults
|
Phase 1 | |
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Completed |
NCT01134263 -
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
|
Phase 3 | |
Completed |
NCT02741128 -
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
|
Phase 2 | |
Completed |
NCT03620487 -
Detection of Dengue Virus in Plasma of Patients in Nepal
|
||
Recruiting |
NCT02608047 -
Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou
|
N/A | |
Completed |
NCT01550016 -
International Research Consortium on Dengue Risk Assessment, Management, and Surveillance
|
N/A | |
Completed |
NCT01421732 -
Laboratory Diagnosis and Prognosis of Severe Dengue
|
N/A | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT01224639 -
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
|
Phase 1 | |
Completed |
NCT01943825 -
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT03465254 -
Dengue Serostatus Study in the Philippines
|
||
Completed |
NCT01702857 -
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)
|
Phase 1 |